» Articles » PMID: 37773045

TLR9 Ligand Sequestration by Chemokine CXCL4 Negatively Affects Central B Cell Tolerance

Abstract

Central B cell tolerance is believed to be regulated by B cell receptor signaling induced by the recognition of self-antigens in immature B cells. Using humanized mice with defective MyD88, TLR7, or TLR9 expression, we demonstrate that TLR9/MYD88 are required for central B cell tolerance and the removal of developing autoreactive clones. We also show that CXCL4, a chemokine involved in systemic sclerosis (SSc), abrogates TLR9 function in B cells by sequestering TLR9 ligands away from the endosomal compartments where this receptor resides. The in vivo production of CXCL4 thereby impedes both TLR9 responses in B cells and the establishment of central B cell tolerance. We conclude that TLR9 plays an essential early tolerogenic function required for the establishment of central B cell tolerance and that correcting defective TLR9 function in B cells from SSc patients may represent a novel therapeutic strategy to restore B cell tolerance.

Citing Articles

The path ahead for understanding Toll-like receptor-driven systemic autoimmunity.

Hamerman J, Barton G Curr Opin Immunol. 2024; 91:102482.

PMID: 39353255 PMC: 11863706. DOI: 10.1016/j.coi.2024.102482.


Human and Murine Toll-like Receptor-Driven Disease in Systemic Lupus Erythematosus.

von Hofsten S, Fenton K, Pedersen H Int J Mol Sci. 2024; 25(10).

PMID: 38791389 PMC: 11120885. DOI: 10.3390/ijms25105351.

References
1.
Meffre E, OConnor K . Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies. Immunol Rev. 2019; 292(1):90-101. PMC: 9145185. DOI: 10.1111/imr.12821. View

2.
Phelan J, Young R, Webster D, Roulland S, Wright G, Kasbekar M . A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. 2018; 560(7718):387-391. PMC: 6201842. DOI: 10.1038/s41586-018-0290-0. View

3.
Vandercappellen J, Van Damme J, Struyf S . The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. Cytokine Growth Factor Rev. 2010; 22(1):1-18. DOI: 10.1016/j.cytogfr.2010.10.011. View

4.
Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V . Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med. 2005; 201(5):703-11. PMC: 2212839. DOI: 10.1084/jem.20042251. View

5.
Combes A, Camosseto V, Nguessan P, Arguello R, Mussard J, Caux C . BAD-LAMP controls TLR9 trafficking and signalling in human plasmacytoid dendritic cells. Nat Commun. 2017; 8(1):913. PMC: 5640662. DOI: 10.1038/s41467-017-00695-1. View